Age | Diabetes Mellitus Duration
Item
men and women aged 30-70 years, with a duration of known diabetes > 2 years
boolean
C0001779 (UMLS CUI [1])
C0011849 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
Oral hypoglycemic Quantity | Metformin Dose Stable | Sulfonylureas Dose Stable
Item
and treated with stable doses of two oral antihyperglycemic agents (metformin and sulfonylurea) for at least 90 days were selected for the study
boolean
C0359086 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0038766 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
Body mass index
Item
body mass index less than 40 kg/m2
boolean
C1305855 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hba1c level between 7.5 and 10%
boolean
C0474680 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
and fasting plasma glucose of 120 mg/dl or greater.
boolean
C0583513 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
exclusion criteria included pregnancy or breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Insulin | Hypoglycemic Agents
Item
previous use of insulin or other antihyperglycemic drugs
boolean
C0021641 (UMLS CUI [1])
C0020616 (UMLS CUI [2])
Investigational New Drugs
Item
investigational drug within the previous 3 months
boolean
C0013230 (UMLS CUI [1])
Pharmaceutical Preparations Affecting Glycaemia control | Glucocorticoids, Systemic | Weight-Loss Agents
Item
use of agents affecting glycemic control (systemic glucocorticoids, and weight-loss drugs)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C3267174 (UMLS CUI [1,3])
C3540777 (UMLS CUI [2])
C0376606 (UMLS CUI [3])
Disease Somatic | Mental disorders
Item
presence of any clinically relevant somatic or mental diseases
boolean
C0012634 (UMLS CUI [1,1])
C2986476 (UMLS CUI [1,2])
C0004936 (UMLS CUI [2])
Diabetes mellitus, insulin-dependent, late onset
Item
to minimize the likelihood of including subjects with late-onset type 1 diabetes
boolean
C1865291 (UMLS CUI [1])
Anti-GAD antibody positive | Fasting C-peptide level
Item
candidate with a positive test for anti-gad antibody or with fasting plasma c-peptide less than 0.25 pmol/ml were excluded
boolean
C1167896 (UMLS CUI [1])
C2208720 (UMLS CUI [2])
Safety Laboratory test result abnormal
Item
also excluded were patients with abnormal safety laboratory tests
boolean
C0036043 (UMLS CUI [1,1])
C0438215 (UMLS CUI [1,2])
Elevated liver enzymes | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised | Creatinine measurement, serum
Item
including liver enzymes (alt, ast, afos) higher than three times the upper limit of normal and serum creatinine > 1.4 mg/dl)
boolean
C0235996 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
C0151849 (UMLS CUI [4])
C0201976 (UMLS CUI [5])
Drug abuse
Item
history of drug abuse
boolean
C0013146 (UMLS CUI [1])
Poor compliance Glucose measurement Daily
Item
poor compliance with the 8-point daily glucose profile measurement
boolean
C0032646 (UMLS CUI [1,1])
C0337438 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])